PRA Health Sciences Inc (NASDAQ:PRAH) EVP David W. Dockhorn Sells 72,850 Shares

PRA Health Sciences Inc (NASDAQ:PRAH) EVP David W. Dockhorn sold 72,850 shares of PRA Health Sciences stock in a transaction that occurred on Friday, December 28th. The shares were sold at an average price of $90.83, for a total transaction of $6,616,965.50. Following the transaction, the executive vice president now directly owns 72,850 shares in the company, valued at $6,616,965.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

PRA Health Sciences Inc (NASDAQ:PRAH) traded up $0.58 during trading hours on Wednesday, hitting $92.15. 450,237 shares of the stock traded hands, compared to its average volume of 459,271. PRA Health Sciences Inc has a 1-year low of $54.08 and a 1-year high of $92.84. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.38. The firm has a market capitalization of $5,850.00, a P/E ratio of 51.77, a P/E/G ratio of 1.27 and a beta of 0.41.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.88 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.03. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The business had revenue of $494.55 million during the quarter, compared to the consensus estimate of $477.89 million. During the same period in the previous year, the firm posted $0.64 earnings per share. The business’s revenue for the quarter was up 23.7% compared to the same quarter last year. research analysts forecast that PRA Health Sciences Inc will post 3.2 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of PRAH. Capital Research Global Investors raised its holdings in shares of PRA Health Sciences by 318.3% during the second quarter. Capital Research Global Investors now owns 2,175,340 shares of the medical research company’s stock worth $163,172,000 after purchasing an additional 1,655,336 shares during the last quarter. BlackRock Inc. raised its holdings in shares of PRA Health Sciences by 28.2% during the second quarter. BlackRock Inc. now owns 3,662,954 shares of the medical research company’s stock worth $274,759,000 after purchasing an additional 805,573 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of PRA Health Sciences by 55.8% during the third quarter. Wells Fargo & Company MN now owns 1,207,069 shares of the medical research company’s stock worth $91,943,000 after purchasing an additional 432,449 shares during the last quarter. Hood River Capital Management LLC raised its holdings in shares of PRA Health Sciences by 80.3% during the second quarter. Hood River Capital Management LLC now owns 619,924 shares of the medical research company’s stock worth $46,500,000 after purchasing an additional 276,045 shares during the last quarter. Finally, Stephens Investment Management Group LLC raised its holdings in shares of PRA Health Sciences by 236.9% during the third quarter. Stephens Investment Management Group LLC now owns 391,672 shares of the medical research company’s stock worth $29,834,000 after purchasing an additional 275,414 shares during the last quarter. Institutional investors and hedge funds own 98.22% of the company’s stock.

Several equities analysts recently issued reports on PRAH shares. Zacks Investment Research raised shares of PRA Health Sciences from a “hold” rating to a “buy” rating and set a $83.00 price objective on the stock in a report on Tuesday, September 19th. Mitsubishi UFJ Financial Group started coverage on shares of PRA Health Sciences in a report on Friday, December 15th. They set an “overweight” rating and a $102.00 price objective on the stock. Credit Suisse Group reissued an “outperform” rating and set a $90.00 price objective (up from $84.00) on shares of PRA Health Sciences in a report on Monday, October 16th. BidaskClub upgraded shares of PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, December 27th. Finally, Mizuho initiated coverage on shares of PRA Health Sciences in a research note on Thursday, September 21st. They issued a “buy” rating and a $82.00 target price for the company. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $91.92.

COPYRIGHT VIOLATION WARNING: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/01/10/pra-health-sciences-inc-prah-evp-david-w-dockhorn-sells-72850-shares.html.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Insider Buying and Selling by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply